PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2013/2014

The PAREXEL Biopharmaceutical R&D Statistical Sourcebook is the leading resource for statistics, trends, and proprietary market intelligence and analysis on the biopharmaceutical industry. Supported by thousands of graphs, illustrations, and analysis, the Sourcebook provides the latest market intelligence on every aspect of biopharmaceutical development - from product discovery, to R&D performance and productivity, to time-to-market trends. With key analysis and contributions from leading consultancies and experts, the Sourcebook provides real-world data and analysis, including: * New proprietary analysis on US clinical trial starts, segmented by therapeutic category, as well as overall active clinical trials. * Emerging data on worldwide and company-specific R&D pipelines and product launch trends. * New analysis on emerging trends in pharma and biotech licensing deals and other partnerships critical to industry s efforts. * Drug approval statistics compiled from FDA, EMEA, and other regulatory agencies. * New global R&D spending trends and other international R&D data from key markets. * International statistics on drug development output. * And much more! Plus, NEW in the 2013/2014 edition: * A record number of all-new metrics on drug development costs and complexity. * New analyses on the state, nature, and sustainability of industry s pipeline of R&D projects. * All new and detailed profiles on the pipelines and emerging R&D models and structures used by leading pharma companies. * Brand new analyses focused on the drug and biopharma markets and development pipelines within emerging countries, including South Korea and China. * All new assessments of personalized medicine/companion diagnostics, biosimilars, orphan drugs, and other factors reshaping biopharma R&D today. * Emerging data on worldwide and company-specific R&D pipelines, strategies, and product launch trends. * International statistics on drug development output.